Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

University of Chicago9 enrolled

Overview

The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).

The primary objective of the proposed study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD). Ten subjects with MDD and BPD will receive a single 25 mg oral dose of psilocybin. The hypothesis to be tested is that psilocybin will result significant reduction in symptoms of both MDD and BPD after 1 week and sustained for 4 weeks compared to baseline (improvement in symptoms will be indicated by lower scores on established outcome measures of MDD and BPD symptoms that have been used in prior studies).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Borderline Personality Disorder Major Depressive Disorder

Interventions

PsilocybinDRUG

Psilocybin 25mg capsule

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-65 * Diagnosed with current major depressive disorder * Montgomery-Asberg Depression Rating Scale (MADRS) score of \> 20 * Diagnosed with borderline personality disorder * Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) score of \> 20 * Ability to understand and sign the consent form Exclusion Criteria: * Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination * Current pregnancy or lactation, or inadequate contraception in women of childbearing potential * Illegal substance use based on urine toxicology screening (except cannabis use) * Current or past history of bipolar I disorder, schizophrenia, or schizoaffective disorder * Active substance use disorder

Locations (1)

University of Chicago

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Montgomery-Asberg Depression Rating Scale (MADRS)

One of the co-primary outcome measures will be the change from baseline using the Montgomery-Asberg Depression Rating Scale (MADRS). The MADRS is a 10-item, clinician-administered scale that assesses depression symptoms during the last seven days. Each item is rated on a scale from 0 to 6, with 0 being "normal/not present" and 6 being "extreme."

Time frame: Baseline to Week 5

Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS)

One of the co-primary outcome measures will be the change from baseline using the Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS). The BPD-SAS covers a two-week time frame and each of the nine criteria, each representing symptoms of BPD, for BPD is rated on a five-point anchored rating scale of 0-4, with 0 representing no symptoms and 4 representing extreme symptoms.

Time frame: Baseline to Week 5

Secondary Outcomes

Clinical Global Impression - Severity scale (CGI-S)

A clinician administered, single item scale measuring global severity of psychiatric illness. The scale itself assesses overall disorder severity on a scale from 1 to 7 with 1 being "not at all" and 7 being "among the most severe cases"

Time frame: Baseline to Week 5

Clinical Global Impression - Improvement scale (CGI-I)

A clinician administered, single item scale measuring overall improvement of global severity of psychiatric illness. The scale itself assesses overall disorder improvement on a scale from 1 to 7 with 1 being "Very much improved" and 7 being "Very much worse"

Time frame: Week 2 to Week 5

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.